LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia

(2020) et al.   JAMA Cardiology

Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease

(2020) Pengwei Hu et al.   CIRCULATION

Worldwide Prevalence of Familial Hypercholesterolemia

(2020) Sabina O. Beheshti et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated

(2019) Jane Stock   ATHEROSCLEROSIS

Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease

(2019) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia

(2019) Ilse K. Luirink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

(2017) Gilbert R Thompson et al.   EUROPEAN HEART JOURNAL

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration

(2016) Antonio J. Vallejo-Vaz et al.   ATHEROSCLEROSIS SUPPLEMENTS

Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia PhenotypeClinical Perspective

(2016) Amanda M. Perak et al.   CIRCULATION

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

(2016) Amit V. Khera et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Encouraging appropriate treatment for familial hypercholesterolemia

(2010) Paul N Hopkins   Clinical Lipidology

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

(2008) A. Neil et al.   EUROPEAN HEART JOURNAL